Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 7/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 5/20 | 0.36 |
| ▸ | BRD4 | O60885 | 4/20 | 0.36 |
| ▸ | EP300 | Q09472 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2268898 | 0.91 | PDE4B (0.48) | PDE4BROCK2KDM1APDE4DCREBBP | |
| SCHEMBL2271739 | 0.86 | PDE4B (0.61) | PDE4BPDE4D | |
| SCHEMBL2270018 | 0.85 | PDE4B (0.50) | PDE4BROCK2PDE4DALDH1A1 | |
| SCHEMBL2270512 | 0.85 | PDE4B (0.46) | PDE4BROCK2PDE4DCREBBPBRD4 | |
| SCHEMBL13458852 | 0.85 | ROCK2 (0.51) | PDE4BROCK2 | |
| SCHEMBL2267799 | 0.84 | PDE4B (0.49) | PDE4BROCK2PDE4DKARS1TRPV1 | |
| SCHEMBL2266542 | 0.83 | PDE4B (0.50) | PDE4BROCK2PDE4DLMNA | |
| SCHEMBL2266533 | 0.82 | PDE4B (0.47) | PDE4BROCK2KDM1APDE4D | |
| SCHEMBL2266566 | 0.80 | PDE4B (0.40) | PDE4BROCK2BRD4KARS1ALDH1A1 | |
| SCHEMBL2271101 | 0.78 | PDE4B (0.41) | PDE4BKARS1ALDH1A1LMNATRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989463-B2 | Biccyclic compounds as GATA modulators | DR. REDDY'S LABORATORIES LIMITED (IN) | 2011-08-02 | — | — | US | disclosed |
| US-7989463-B2 | Biccyclic compounds as GATA modulators | DR. REDDY'S LABORATORIES LIMITED (IN) | 2011-08-02 | — | — | US | disclosed |
| US-7989463-B2 | Biccyclic compounds as GATA modulators | DR. REDDY'S LABORATORIES LIMITED (IN) | 2011-08-02 | — | — | US | disclosed |
| US-20100144731-A1 | Novel Biccyclic Compounds As GATA Modulators | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-06-10 | — | — | US | disclosed |
| US-20100144731-A1 | Novel Biccyclic Compounds As GATA Modulators | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-06-10 | — | — | US | disclosed |
| US-20100144731-A1 | Novel Biccyclic Compounds As GATA Modulators | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-06-10 | — | — | US | disclosed |
| WO-2010028174-A1 | NOVEL BICCYCLIC COMPOUNDS AS GATA MODULATORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144731-A1 | Novel Biccyclic Compounds As GATA Modulators | GATAD2A, GATAD2B, RUNX1 | PDE4B 1568/4885ROCK2 3039/4885KDM1A 565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.